VenatoRx Pharmaceuticals' founders, Christopher J. Burns, Ph.D., Daniel C. Pevear, Ph.D., and Luigi Xerri, Ph.D., received the Entrepreneur Of The Year® 2019 Award in the Health and Life Sciences category in Greater Philadelphia.
VenatoRx Pharmaceuticals will present ten posters featuring its two development-stage products, cefepime/VNRX-5133 and ceftibuten/VNRX-7145, at ASM Microbe 2019 to be held June 20-24 in San Francisco, CA. VenatoRx will also present an overview if its antibacterial agents portfolio during the Pharma Pipeline Update, concentrating on its orally bioavailable beta-lactamase inhibitor, VNRX-7145, during the New Agents Discovery Summary Session.
VenatoRx Pharmaceuticals will have 12 poster presentations at ECCMID 2019 featuring cefepime/VNRX-5133 and ceftibuten/VNRX-7145.
Dr. Wittmer has more than 20 years’ experience and a demonstrated track record in leading development from early stages through to licensing, registration and commercialization of new therapeutics. In her role at VenatoRx, Dr. Wittmer will oversee nonclinical and clinical development, as well as global regulatory affairs.
President and CEO, Christopher J. Burns, Ph.D., will present the Company's novel, orally-bioavailable beta-lactamase inhibitor, VNRX-7145, during the First Time Disclosure of Clinical Candidates at the American Chemical Society (ACS) National Meeting. The presentation entitled, “Discovery of VNRX-7145: A broad-spectrum orally bioavailable beta-lactamase inhibitor (BLI) for highly resistant bacterial infections (“superbugs”)” is scheduled for Wednesday, April 3, 2019 at 10:35am ET in the Valencia Ballroom A at the Orange County Convention Center in Orlando, FL.
Recognition honors a CEO who has demonstrated visionary leadership and active participation to advance the life sciences and biotech industry.
The objective of this R01 grant is to provide tools that can facilitate therapeutic discovery for Gram-negative bacterial pathogens, including carbapenem-resistant Enterobacteriaceae (CRE), multi-drug resistant (MDR) Acinetobacter baumannii and/or MDR Pseudomonas aeruginosa. This initiative will also support VenatoRx’s discovery programs targeting novel antibacterial agents.
Chief Business Officer, Tony Meehan, MBA, PhD, will present attendees with an overview of VenatoRx's pipeline and unique operating model on Monday, February 11, 2019 at 3:30pm ET in the Gramercy room at the New York Marriott Marquis.